NRIX lands $700M Roche deal for lead drug; net loss climbs 77% on trial acceleration

Filed July 9, 2026 · Period ending May 31, 2026 · Compared to 10-Q Jul 9, 2025 · ~2 min read

Key Changes

• high

  Signed global collaboration with Roche for bexobrutideg (NX-5948) on June 6, 2026: $700M upfront, up to $2.3B total, 40/60 cost-share, 50/50 U.S. profit split, tiered ex-U.S. royalties. Upfront payment expected Q3 FY2026.

  MD&A: Roche Collaboration; Notes: Subsequent Events verify on EDGAR →
• high

  Bexobrutideg advanced to Phase 2 potentially pivotal trial (DAYBreak) in October 2025 for heavily pre-treated CLL (three prior lines including cBTKi, BCL2i, ncBTKi), designed for potential Accelerated Approval using 600mg once-daily dose agreed with FDA.

  MD&A: Clinical Development verify on EDGAR →
• high

  Net loss rose to $176.7M for H1 FY2026 from $99.8M prior year (77% increase) as R&D spending climbed to $171.8M from $147.8M, driven by accelerated bexobrutideg enrollment and trial preparation; collaboration revenue fell to $15.3M from $62.5M (prior year included $30M Sanofi license milestone).

  MD&A: Financial Results verify on EDGAR →